Eaton Vance Management’s Myriad Genetics MYGN Stock Holding History

Eaton Vance Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-958	Closed	-$26K	–	2382
2021 Q4	$26K	Sell	958 -724	-43%	-$21K	﹤0.01%	2328
2021 Q3	$0	Sell	1,682 -233	-12%	-$7.74K	﹤0.01%	2446
2021 Q2	$59K	Buy	1,915 +1,334	+230%	+$38.5K	﹤0.01%	2102
2021 Q1	$18K	Buy	+581	New	+$16.5K	﹤0.01%	2130
2016 Q4	–	Sell	-10,000	Closed	-$206K	–	1012
2016 Q3	$206K	Hold	10,000	–	–	﹤0.01%	954
2016 Q2	$306K	Sell	10,000 -3,000	-23%	-$104K	﹤0.01%	884
2016 Q1	$487K	Hold	13,000	–	–	﹤0.01%	792
2015 Q4	$561K	Hold	13,000	–	–	﹤0.01%	784
2015 Q3	$487K	Hold	13,000	–	–	﹤0.01%	791
2015 Q2	$442K	Hold	13,000	–	–	﹤0.01%	775
2015 Q1	$460K	Buy	+13,000	New	+$465K	﹤0.01%	809

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Eaton Vance Management's MYGN Position: Q1 2022 in Review

Eaton Vance Management sold out of Myriad Genetics (MYGN) in Q1 2022, closing a stake of 958 shares — an estimated $26K sold.

Eaton Vance Management first reported a position in MYGN in Q1 2015 and held it in 11 quarters. The position peaked at $561K in Q4 2015. 205 funds tracked by Wall St. Rank hold MYGN as of Q1 2022.

Eaton Vance Management reported no remaining Myriad Genetics position as of Q1 2022 after selling out during the quarter.
Eaton Vance Management sold 958 Myriad Genetics shares in Q1 2022, an estimated $26K.
Eaton Vance Management first reported a position in Myriad Genetics in Q1 2015 and held it in 11 quarters.
Eaton Vance Management's Myriad Genetics position peaked at $561K in Q4 2015.
205 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.